Cart
sales@molnova.com
DL-AP3
CAS No. 20263-06-3
DL-AP3( —— )
Catalog No. M23907 CAS No. 20263-06-3
DL-AP3 is a competitive group I metabotropic glutamate receptor antagonist and inhibitor of phosphoserine phosphatase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 28 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDL-AP3
-
NoteResearch use only, not for human use.
-
Brief DescriptionDL-AP3 is a competitive group I metabotropic glutamate receptor antagonist and inhibitor of phosphoserine phosphatase.
-
DescriptionDL-AP3 is a competitive group I metabotropic glutamate receptor antagonist and inhibitor of phosphoserine phosphatase.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGluR
-
RecptorGlutamate receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number20263-06-3
-
Formula Weight169.07
-
Molecular FormulaC3H8NO5P
-
Purity>98% (HPLC)
-
SolubilityDMSO:<1 mg/mL;Ethanol:<1 mg/mL;H2O:12.05 mg/mL
-
SMILESC(C(C(=O)O)N)P(=O)(O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Di C , Xu J , Xu Q , et al. DL-2-amino-3-phosphonopropionic acid protects primary neurons from oxygen-glucose deprivation induced injury[J]. Bosn J Basic Med, 2017, 17(1).
molnova catalog
related products
-
KM02894
KM02894 is a glutamate release inhibitor. Cancer cells release high levels of glutamate that can disrupt normal bone turnover, which can lead to cancer-induced bone pain.KM02894 may be used in the study of tumor-related diseases.
-
VU6005649
VU6005649 is an agonist of CNS penetrant mGlu7/8 receptor (EC50s: 0.65 μM and 2.6 μM for mGlu7 receptor and mGlu8 receptor, respectively).
-
ABP688
ABP688 is a non-competitive and selective mGluR5 antagonist(Ki = 1.7 nM). ABP688 can be used as a PET tracer for clinical imaging.
